Home > Boards > US OTC > Medical - Drugs > Innovation Pharmaceuticals Inc. (IPIX)

I admire Leo Ehrlich for his accomplishments with

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (6) | Next 10 | Previous | Next
farrell90 Member Profile
Member Level 
Followed By 104
Posts 3,063
Boards Moderated 0
Alias Born 01/28/06
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 7/15/2020 10:56:17 AM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 7/10/2020 5:09:32 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 7/10/2020 3:07:19 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/19/2020 5:28:09 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/26/2020 2:16:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/21/2020 9:33:35 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/14/2020 9:03:05 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/28/2020 9:30:58 AM
Cannabis and CBD Stocks are Old News, The Next Hot Peripheral Sector is Here! InvestorsHub NewsWire - 4/16/2020 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/6/2020 2:21:58 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/1/2020 4:39:40 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/1/2020 12:00:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/6/2020 12:01:06 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/27/2020 12:01:14 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/13/2020 4:06:02 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 2/13/2020 4:02:49 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 12/26/2019 5:19:40 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/26/2019 5:16:58 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 12/16/2019 8:32:20 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/13/2019 9:24:21 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 10/22/2019 6:01:03 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 10/17/2019 5:24:36 PM
Annual Report (10-k) Edgar (US Regulatory) - 9/30/2019 4:38:42 PM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/20/2019 4:36:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/20/2019 4:34:50 PM
farrell90 Member Level  Saturday, 05/16/20 12:42:04 AM
Re: scottsmith post# 297069
Post # of 312085 
I admire Leo Ehrlich for his accomplishments with IPIX. It is unusual for one individual to possess the skills, dedication and perseverance to direct a small biotech company for a number of years to this point. He has run the company on a financial shoestring with very little help and has maneuvered the company to the point where IPIX has partnered with AS to develop Brilacidin for UP ; Oral Brilacidin for UC is ready to enter a phase 2 FDA study; Brilacidin for OM is ready for a stage 3 FDA study; when funds are available Kevetrin will be developed as an oral medication; then Kevetrin may be ready to enter into a stage 2 FDA trial for Ovarian Cancer.

In a few days we will know if Brilacidin is active against Covid 19 infected respiratory epithelial cells after a battery of tests.

I have been told by a biologist I trust that Vero monkey cells and Human cells are very similar genetically which means there is a substantial chance the second round of RBL tests will be positive. If positive Brilacidin will move to clinical trials.

Obviously it goes without saying, the future testing of Brilacidin against Covid19 may not work out and IPIX will have a substantial set back. However, it will have received a substantial amount of research and development with little expense.

On the other hand if Brilacidin proves to be an effective treatment for Covid 19, it will save an untold number of lives and eliminate much loss and suffering. Mr Ehrlich and the IPIX shareholders will be richly rewarded.

The Polymedix scientists, DeGrado,Klein,Scott and others who developed Brilacidin will have a shot at the Nobel prize. The field of defensin mimetics and protein chemistry they have pioneered will be validated and a bright future for other revolutionary medications and treatments will follow. Brilacidin's research and development will continue and multiple future indications are possible.

Mr Ehrlicht has accomplished a great deal. It is disappointing and discouraging you and others do not appreciate his efforts and abilities.

All IMO

Best wishes,Farrell

Imagine Leo telling a reporter he is a genius. A genius with a one employee company.



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (6) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist